Conference reports

18th International European AIDS Conference (EACS 2021)

EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?

European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV

18th International European AIDS Conference (EACS 2021)

Lenacapavir: drug resistance after viral rebound in treatment experienced participants

Implications of historical M184V on use of dual dolutegravir/lamivudine ART

Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks

Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study

HIV-specific mental health services across the EU

18th International European AIDS Conference (EACS 2021)

EACS 2021: a call for collaborations and for both HIV and COVID-19 

Reduced responses to COVID-19 vaccines at low CD4 counts

EACS Guidelines: 11th edition (October 2021)

Community “Respect my HIV” march: 30 October 2021 in London

11th IAS Conference on HIV Science (IAS 2021)

IAS 2021 website now open access

Substudies from the ODYSSEY trial: results July 2021

Trial design for next generation PrEP

11th IAS Conference on HIV Science (IAS 2021)

IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP

IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide

IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies

IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data

IAS 2021: New demands for better transgender heath care: No data no more

13th International Workshop on HIV Paediatrics 2021

Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial

5th Joint BHIVA/BASHH Conference 2021

Few vertical HIV transmissions in the UK but contributing factors remain associated with inequality

5th joint BHIVA/BASSH conference 2021

Weight changes on ART and how to lose weight successfully

Selected presentations at BHIVA: COVID-19, PrEP in the UK, community involvement and more…

28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) virtual

No differences in outcomes among women with and without HIV with high-risk pregnancies and COVID-19

Dolutegravir-based regimens safe and effective in pregnancy and postpartum

Dolutegravir superior to standard of care in children and adolescents: results from the ODYSSEY trial

Joint BHIVA/BASSH Spring Conference 2021

BHIVA registry reports HIV is independently linked to worse presentation and outcomes from COVID-19

HIV is linked to higher mortality from COVID-19 compared to HIV negative: 60% of deaths were black ethnicity

Case-control study of HIV positive people hospitalised with COVID-19

28th Conference on Retroviruses on Opportunistic Infections (CROI 2021)

Featured CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP

CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF

CROI 2021: New compounds for prevention and treatment of COVID-19

Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study

Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study

Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study

CROI 2021: Presentations from the LEAP workshop 2021

CROI 2021: Presentations on

28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)

CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV

CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…

CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance

CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021

CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission

CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial

CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…

CROI 2021: Community HIV cure workshops online

R4P virtual conference (2021)

VRC01 antibody only prevents minority of HIV infections: AMP study results

Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)

Promising data for multipurpose technologies to prevent HIV and pregnancy

12th International Workshop on HIV paediatrics

New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1

BHIVA 2020 virtual conference now online

Post navigation